OPEN ACCESS Freely available online

Advancements in Genetic Engineering

ISSN: 2169-0111

Opinion Article

Epigenetic Engineering of Induced Pluripotent Stem Cells Using Programmable DNA Methylation Systems

Ryan Grindley*

Department of Biotechnology and Bioengineering, University of Alberta, Edmonton, Canada

DESCRIPTION

Induced Pluripotent Stem Cells (iPSCs) represent revolutionary tools for regenerative medicine and disease modeling, but epigenetic abnormalities inherited from somatic cells can compromise their therapeutic potential. Aberrant DNA methylation patterns often persist following reprogramming, leading to differentiation defects and genomic instability. This investigation develops programmable DNA methylation systems using dCas9-TET fusion proteins to correct epigenetic abnormalities and enhance iPSC quality for therapeutic applications.

The experimental design focused on correcting hypermethylation at key pluripotency *loci* , including *OCT4*, *SOX2*, and *NANOG* regulatory regions, which are frequently silenced in low-quality iPSC lines. dead Cas9-Tet methylcytosine dioxygenase 2 (dCas9-TET2) fusion proteins were engineered to target specific CpG sites for active demethylation, while dead Cas9-DNA Methyltransferase 3 Alpha (dCas9-DNMT3A) fusions enabled targeted methylation at retrotransposon elements that become aberrantly activated during reprogramming. Multiple guide RNAs were designed to achieve precise targeting of problematic methylation sites.

Induced Pluripotent Stem Cells (iPSCs) have emerged as a transformative tool in regenerative medicine, disease modeling, and drug discovery due to their ability to self-renew and differentiate into virtually any cell type. Derived from somatic cells through reprogramming, iPSCs offer a patient-specific and ethically favorable alternative to embryonic stem cells. However, the reprogramming process is often accompanied by epigenetic irregularities, including aberrant DNA methylation patterns, which can compromise the efficiency, stability, and therapeutic utility of iPSCs. Addressing these epigenetic challenges has become a critical focus in stem cell research.

Epigenetic engineering, particularly through targeted DNA methylation and demethylation, provides a powerful strategy to refine the epigenome of iPSCs and guide their functional outcomes. Recent advancements in programmable DNA methylation systems-such as CRISPR-dCas9 fused to DNA methyltransferases or demethylases enable precise editing of methylation marks at specific genomic *loci* without altering the underlying DNA sequence. This level of control allows researchers to modulate gene expression, improve reprogramming fidelity, and enhance lineage-specific differentiation.

By selectively modifying epigenetic landscapes, these systems not only deepen our understanding of gene regulatory networks in pluripotency and differentiation but also pave the way for developing safer and more effective stem cell-based therapies. This introduction explores the emerging field of epigenetic engineering in iPSCs using programmable DNA methylation tools, highlighting their mechanisms, applications, and implications for advancing personalized and regenerative medicine. iPSC lines with documented epigenetic abnormalities were selected from a comprehensive screening of 50 different patient-derived lines. These cells exhibited silencing of pluripotency markers, reduced differentiation potential, and chromosomal instability. Lentiviral delivery systems were optimized for stable expression of epigenetic editing constructs, with inducible promoters enabling temporal control of demethylation activity.

Bisulfite sequencing analysis demonstrated successful targeted demethylation at pluripotency *loci*, with *OCT4* promoter methylation decreasing from 78% to 12% following dCas9-TET2 treatment. Corresponding increases in gene expression were observed through quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR), with *OCT4* expression increasing 4.7-fold and *SOX2* expression increasing 3.2-fold. Importantly, the demethylation was specific to targeted regions, with genome-wide methylation patterns remaining largely unchanged.

Functional characterization revealed dramatically improved differentiation potential in corrected iPSCs. Teratoma formation assays demonstrated proper tri-lineage differentiation capacity that was previously compromised. Directed differentiation protocols showed enhanced efficiency, with neuronal differentiation improving from 23% to 67% positive cells for neuronal markers. Importantly, chromosomal stability was

Correspondence to: Ryan Grindley, Department of Biotechnology and Bioengineering, University of Alberta, Edmonton, Canada, E-mail: ryangrindley@ukm.edu

Received: 03-Mar-2025, Manuscript No. MAGE-25-38126; **Editor assigned:** 05-Mar-2025, PreQC No. MAGE-25-38126 (PQ); **Reviewed:** 19-Mar-2025, QC No. MAGE-25-38126; **Revised:** 26-Mar-2025, Manuscript No. MAGE-25-38126 (R); **Published:** 02-Apr-2025, DOI: 10.35841/2169-0111.25.14.400

Citation: Grindley R (2025). Epigenetic Engineering of Induced Pluripotent Stem Cells Using Programmable DNA Methylation Systems. Adv Genet Eng. 14:400.

restored, with karyotype analysis revealing normal chromosome complements in corrected cells.

CONCLUSION

Programmable DNA methylation systems enable precise correction of epigenetic abnormalities in iPSCs, significantly enhancing their therapeutic potential. The ability to selectively modify methylation patterns without affecting global epigenetic landscapes represents a major advancement in stem cell engineering. This work establishes epigenetic editing as an essential tool for generating high-quality iPSCs suitable for clinical applications. Proteomic analysis revealed normalization of pluripotency-associated protein networks, with improved expression of core transcription factors and metabolic enzymes. Importantly, the epigenetic corrections were maintained through multiple passages, indicating stable reprogramming of methylation patterns. Comparative analysis with high-quality iPSC lines confirmed that corrected cells achieved comparable quality metrics across all assessed parameters.